Immunome files NDA for varegacestat in desmoid tumors
Immunome (IMNM) filed an NDA for varegacestat targeting desmoid tumors and highlighted its ROR1-focused ADC pipeline and innovative payload platform.
This is a real-time flash headline. A verified provider body is not available, so SquawkNews does not present it as a full article.